Bupivacaine News and Research

RSS

Injection technique provides pain relief following knee replacement surgery

It's estimated that more than half of adults in the United States diagnosed with knee osteoarthritis will undergo knee replacement surgery.

22 Dec 2014

FDA approves additional manufacturing suite for Pacira’s EXPAREL

Pacira Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved an additional bulk manufacturing suite, referred to as Suite C, for EXPAREL (bupivacaine liposome injectable suspension). The suite is housed at the company's Science Center Campus in San Diego, where EXPAREL is currently manufactured.

31 Mar 2014

New approach to breast reconstruction surgery decreases use of postoperative opioid painkiller

A new approach to breast reconstruction surgery aimed at helping patients' bodies get back to normal more quickly cut their postoperative opioid painkiller use in half and meant a day less in the hospital on average, a Mayo Clinic study found.

4 Mar 2014

Pacira Pharmaceuticals initiates Phase 3 clinical trial of EXPAREL in femoral nerve block

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the Phase 3 clinical trial assessing the safety and efficacy of EXPAREL® (bupivacaine liposome injectable suspension) in femoral nerve block for total knee arthroplasty met its primary efficacy endpoint.

27 Feb 2014

Study: Liposomal bupivacaine can provide longer-lasting nerve blocks

Can a new liposomal bupivacaine product provide long-lasting nerve block with a single injection? An initial study in humans shows promise-but also some "confusing results," reports the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

29 Oct 2013

FDA accepts DURECT's New Drug Application for POSIDUR

DURECT Corporation today announced that the New Drug Application for the investigational product POSIDUR (SABER-Bupivacaine) has been accepted by the U.S. Food and Drug Administration indicating that the application is sufficiently complete to permit a substantive review.

20 Jun 2013

Pacira Pharmaceuticals reports results of EXPAREL Phase 2/3 clinical trial for TKA

Pacira Pharmaceuticals, Inc. today announced findings from the completed first part of its Phase 2/3 clinical trial assessing the use and administration of EXPAREL (bupivacaine liposome injectable suspension) as a single-dose injection femoral nerve block for total knee arthroplasty surgery.

29 May 2013

ORAEs increase costs of care, hospital stays and risks of readmission and mortality, research finds

Pacira Pharmaceuticals, Inc. today announced the publication of findings from a retrospective analysis of more than 37,000 patients who underwent common inpatient surgeries at a large, 26-hospital healthcare system and received opioids for postsurgical pain management.

25 Apr 2013

New data reveals impact of opioid-related adverse events on length, cost of hospitalization after surgery

Pacira Pharmaceuticals, Inc. today announced data from a large-scale analysis of a national database of patients from 380 hospitals in the United States who underwent 319,898 inpatient surgeries and received opioids for postsurgical pain management.

27 Mar 2013

Tourniquet timing alters foot surgery pain outcomes

The timing of thigh tourniquet application may affect pain control in patients undergoing forefoot surgery, research published in Foot and Ankle Surgery suggests.

11 Oct 2012

Benefit of in-joint anesthesia queried in canine arthroscopy

Measurements of gait and lameness after arthroscopy in dogs show no evidence that either intra-articular bupivacaine or morphine provide an analgesic effect in the immediate postoperative period, despite bupivacaine having some effect on pain, report researchers.

25 Jul 2012

Pacira first quarter total revenues increase to $7.8 million

Pacira Pharmaceuticals, Inc. today announced consolidated financial results for the quarter ended March 31, 2012 and reviewed recent accomplishments, including the commercial launch in the United States of EXPAREL (bupivacaine liposome injectable suspension) for postsurgical pain and the successful completion of an equity financing.

9 May 2012

Pacira secures $27.5 million debt financing facility

Pacira Pharmaceuticals, Inc. today announced that it has secured a $27.5 million debt financing facility through Oxford Finance. Pacira will use the proceeds from this financing to refinance the remaining principal of its outstanding term loan and for general corporate purposes.

3 May 2012

Pacira launches EXPAREL in the U.S.

Pacira Pharmaceuticals, Inc. today announced the commercial launch of EXPAREL (bupivacaine liposome injectable suspension) in the United States. Starting today, EXPAREL will begin shipping to hospital and ambulatory care customers through their normal wholesaler and distributor channels.

9 Apr 2012

Innocoll completes XaraColl End-of-Phase 2 meeting with FDA

Innocoll, Inc. announced that it has held an End-of-Phase 2 meeting with the FDA to present the results of the Phase 2 clinical studies completed for XaraColl and to discuss the proposed safety and efficacy studies to be conducted in Phase 3. XaraColl is being developed for postoperative analgesia and Innocoll plans to undertake its Phase 3 program in patients undergoing hernia repair.

17 Feb 2012

Bupivacaine may effectively manage pain after total knee replacement

Researchers at the Rothman Institute at Jefferson have shown that local anesthesia delivered through a catheter in the joint, intraarticularly, may be more beneficial than traditional opioids such as morphine and Oxycontin for pain management following total knee replacement surgery.

10 Feb 2012

Takeda returns POSIDUR development and commercialization rights to DURECT

DURECT Corporation today reported that Takeda has given notice that it is returning its development and commercialization rights to POSIDUR in Europe and their other licensed territories.

31 Jan 2012

Pacira provides updated timing for commercial launch of EXPAREL

Pacira Pharmaceuticals, Inc. today provided updated timing for its commercial launch of EXPAREL (bupivacaine liposome injectable suspension), a non-opioid analgesic that was approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce postsurgical analgesia.

9 Jan 2012

Diseases of the Colon & Rectum publishes results from Pacira's EXPAREL Phase 3 trial

Pacira Pharmaceuticals, Inc. today announced the publication of data from a placebo-controlled, pivotal Phase 3 trial of EXPAREL (bupivacaine liposome injectable suspension), a non-opioid local analgesic that was recently approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce postsurgical analgesia.

19 Dec 2011

Pacira prices public offering of 7,000,000 shares of common stock

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced the pricing of its public offering of 7,000,000 shares of its common stock at a price of $6.50 per share.

16 Nov 2011